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Short-term mechanical circulatory Support
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Summary
Heart failure continues to be an ever-growing public health concern. The continued 
aging of the population has contributed to the increasing incidence and prevalence of 
heart failure. Mechanical circulatory support is used to treat patients with advanced heart 
failure. A mechanical pump is surgically implanted to provide pulsatile or non-pulsatile 
flow of blood to supplement or replace the blood flow generated by the native heart. The 
main purpose of a mechanical circulatory support is to unload the failing heart and help 
maintain forward cardiac output and vital organ perfusion. A big variety of devices exists: 
from the percutaneous and short-term support, which can be used in the operating room 
or the cath-lab and afterwards in the intensive or coronary care units, to the internal and 
long-term devices, which can be used as a bridge-to-recovery or cardiac transplant, or as 
definitive therapy in patients with contraindication to cardiac transplant. This treatment in-
volves not only the cardiac surgeons, but also the cardiologists, anaesthesiologists, intensi-
vists and perfusionists. Appropriate patient selection represents the critical determinant of 
successful outcomes with the VAD therapy. The predictive risk stratification is extremely 
important for achieving the minimal peri-operative mortality rate. As VAD technology 
progresses, the collaboration of multidisciplinary teams composed of engineers, scientists, 
physicians, and nurses will continue to refine the technology and improve patient care 
and operation outcomes. Advances in device design will allow for an easier implantation 
and create smaller, more efficient, durable, and reliable units.
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Heart failure continues to be an ever-growing public health concern. The conti-
nued aging of the population has contributed to the increasing incidence and pre-
valence of heart failure [1]. Mechanical circulatory support is used to treat patients 
with advanced heart failure. A mechanical pump is surgically implanted to provide 
pulsatile or non-pulsatile flow of blood to supplement or replace the blood flow ge-
nerated by the native heart. Types of circulatory support pumps include pneumatic 
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and electromagnetic pumps. Rotary pumps are also available. Investigators and the 
medical device industry have been pursuing the development of mechanical cardiac 
support for more than four decades. Mechanical circulatory support has significantly 
evolved over the last years. It is now a real and useful therapeutic option not only 
for the treatment of cardiogenic shock, but also for advanced chronic heart failure, 
and even preventively in high-risk cases of percutaneous coronary intervention and 
cardiac surgery. The main purpose of a mechanical circulatory support is to unload 
the failing heart and help maintain forward cardiac output and vital organ perfusi-
on. Originally introduced as a temporary bridge-to-recovery and then as a bridge-to-
transplantation, the mechanical circulatory support has evolved into permanent or 
“destination” therapy for a growing number of patients with refractory heart failure 
[2]. A big variety of devices exists: from the percutaneous and short-term support, 
which can be used in the operating room or the cath-lab and afterwards in the inten-
sive or coronary care units, to the internal and long-term devices, which can be used 
as a bridge-to-recovery or cardiac transplant, or as definitive therapy in patients with 
contraindication to cardiac transplant. This treatment involves not only the cardiac 
surgeons, but also the cardiologists, anaesthesiologists, intensivists and perfusionists. 
Indications for device support continue to evolve from day to day. Patients considered 
for mechanical circulatory support are not able to sustain adequate systemic oxygen 
delivery to maintain normal end-organ function despite maximal medical therapy. 
Haemodynamic criteria for device implantation include: systolic blood pressure lower 
than 80 mm Hg; mean arterial pressure lower than 65 mm Hg; cardiac index lower 
than 2.0 L/min/m2; pulmonary capillary wedge pressure higher than 20 mm Hg; and 
systemic vascular resistance over 2,100 dynes-sec/cm [3]. The decision to implement 
mechanical circulatory support must be made with consideration to the ultimate goal 
of therapy. Mechanical circulatory support always represents a kind of a bridge (brid-
ge-to-: decision, recovery, transplant, conventional treatment, death; or, finally, brid-
ge-to-nowhere). As mentioned above, indications for mechanical support are continu-
ously evolving, and herein we present some of them.
1. Cardiogenic shock associated with acute myocardial infarction (AMI) com-
plicates clinical presentation of 6 to 20 % of patients suffering from AMI, and is 
reported with a mortality rate between 70-80 % [4].
2. Postcardiotomy cardiogenic shock is experienced by 2 to 6 % of patients un-
dergoing coronary or valvular cardiac procedures [5]. Special consideration should 
be given to patients with severely impaired ventricular function undergoing high-
risk cardiac procedures. Transplant evaluation should be initiated pre-operatively, 
and the procedure should be performed with an LVAD „back-up“. 
27
Rad 509. Medical Sciences, 36(2011) : 25-38
B. Biočina, M. Petričević: Short-term mechanical circulatory support
3. Chronic cardiac failure. In this subgroup of patients, short-term mechanical 
support can be instituted as a bridge-to-transplantation. The normalisation of ha-
emodynamics and the maintenance of the end-organ function decrease post-tran-
splant mortality [6].
4. Myocarditis is characterised by an unpredictable clinical course, and short-
term mechanical circulatory support (especially biventricular support due to biven-
tricular disease involvement) presents the chance for a bridge-to-recovery.
Of note, there are some reports of device implantation in patients suffering from 
ventricular arrhythmias refractory to medical therapy [7].
Appropriate patient selection represents the critical determinant of successful 
outcomes with the VAD therapy. The predictive risk stratification is extremely im-
portant for achieving the minimal peri-operative mortality rate. Aiming the optimal 
risk/benefit ratio, some reports have sought to identify the predictives of risks and 
benefits [8]. The timing of intervention is an important determinant of the clinical 
outcomes. For example, the optimisation of patient status with diuresis; the correc-
tion of coagulation abnormalities; the pulmonary rehabilitation; and the implemen-
tation of intra-aortic balloon pump may be useful. It is obligatory to control systemic 
sepsis or bacteraemia, due to a high risk of device contamination. On the other hand, 
the mentioned treatments and procedures may lead to unnecessary postponements, 
which may further lead to a marked increase in mortality [9-10]. Contraindications 
for device implantation, such as irreversible end-organ damage and unrecoverable 
neurologic injury, have to be considered as well.
THE COMPONENTS OF THE MECHANICAL CIRCULATORY SUPPORT
Ventricular assist devices (VAD) used in the outpatient setting are implanted 
devices placed through a median sternotomy typically during cardiopulmonary 
bypass. VAD is connected to the heart by an inflow cannula that decompresses the 
ventricular cavity and an outflow cannula that returns blood to either the ascending 
aorta or the main pulmonary artery. The pumping chamber of the VAD is implanted 
sub-diaphragmatically to a pre-peritoneal or intra-abdominal position, or it may be 
situated in a para-corporeal position outside the body. Smaller devices are being 
developed for thoracic implantation, some with outflow to the descending aorta.
THE PHYSIOLOGY OF VADS
VADs support the failing heart by unloading the ventricle and generating the 
flow to the systemic and / or pulmonary circulation. This creates parallel pumping 
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chambers that compete for the same venous return (pre-load), and face the arterial 
resistance (after-load) of their respective pulmonary and systemic vascular beds. 
Under optimal conditions, the native ventricle is a passive conduit, through which 
the mechanical pump fills throughout the cardiac cycle, and the decompressed ven-
tricle should contribute little to the systemic cardiac output. If a ventricular stroke 
volume is generated, and the aortic / pulmonic valve leaflets are seen to open on 
echocardiography, either the return of the native ventricular function or an ina-
dequate decompression of the native ventricle and device dysfunction should be 
suspected. Isolated right ventricular dysfunction, requiring insertion of a right ven-
tricular assist device (RVAD) to support the failing ventricle, is a rare event. Cases 
have been reported postcardiotomy after an acute myocardial infarction, coronary 
artery bypass grafting, and valvular surgery. More commonly, an RVAD may be 
inserted around the time a left ventricular assist device (LVAD) to provide biven-
tricular assistance is placed. Unlike a single VAD, biventricular mechanical devi-
ces create a complex system with two independent pumps, one of them right-sided 
and the other one left-sided. The left atrial venous return is normally greater than 
the right atrial pre-load, because of the bronchial circulation; overall, the left-sided 
output (LVAD plus native left ventricle) must always be greater than the right-sided 
output (RVAD plus native right ventricle), or else, pulmonary oedema may develop. 
In addition to navigating complex biventricular cannula insertion anatomy, native 
right and left ventricular function may also recover at different rates. 
CHANGES IN THE VENTRICULAR FUNCTION AFTER 
IMPLANTATION
The histological and biochemical signs of recovery of mechanically supported 
myocardial tissue are an issue of inquiry. Although a VAD’s main purpose is to 
assume the pumping function of the heart, the reduction in myocardial stretch after 
the VAD decompression may lead to a recovery process referred to as reverse ven-
tricular remodelling [11]. Improvement in intrinsic myocyte function may occur due 
to alterations in abnormal gene expression; changes in collagen content; regression 
of cellular hypertrophy; and reduction in myocytolysis and inflammatory cytokines 
[12-15]. Although such changes may occur, most patients do not fully recover and 
are ineligible for explantation [16]. To help promote reverse remodelling, efforts are 
underway to assess the use of disease-altering pharmacological regimens in VAD 
patients. At the present time, all patients who appear to be bridge-to-recovery can-
didates are restarted on neuro-hormonal antagonists, which are then up-titrated to 
published guidelines as tolerated. In 2006, Birks et al. reported on the successful re-
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versal of remodelling in selected VAD patients with non-ischemic cardiomyopathy 
treated with clenbuterol [17].
DEVICE SELECTION
The anticipated treatment endpoint must be considered when choosing a speci-
fic device. In this article, short-term mechanical support devices are described. The-
se include counter-pulsation and centrifugal, axial, and pneumatic pumps. These 
devices, which are easily implemented, aim at providing either a short-term bridge-
to-recovery or a short-term bridge-to-more permanent assistance or transplant as 
destination therapy.
Intraaorticsed pre-operatively as an adjunct to high-risk percutaneous interven-
tions or coronary artery bypass grafting. Contraindications for IABP use are aortic 
insufficiency, aortic dissection and severe aortic and peripheral vascular atherosc-
lerosis. The latter concerns the pre-operative use; it is however possible to insert the 
balloon via the ascending aorta during surgery.
The iVAC 3L™ is a mid-range minimal heart circulatory assist device that ef-
fectively generates up to three litres per minute. The iVAC 3L™ off balloon pump 
(IABP), first described in 1968 [18], is the most common form of short-term mecha-
nical circulatory assistance. Couner-pulsation, provided by balloon inflation within 
the descending thoracic aorta during diastole with deflation at the onset of systole. 
The result is reduction in myocardial work through after-load reduction, and impro-
vement in myocardial oxygen supply through the augmentation of diastolic blood 
pressure and coronary perfusion pressure [19]. IABP counter-pulsation timing is 
performed from the ECG or the arterial waveform. IABP counter-pulsation is used 
today in a variety of clinical settings, including the cardiogenic shock associated with 
myocardial infarction; the postcardiotomy shock; the mechanical complications of 
infarction, such as acute mitral regurgitation and ventricular septal defect; the post-
infarction angina; and for the treatment of ventricular arrhythmias in the setting of 
ongoing ischemia. IABP has also been u ers critical haemodynamic support in the 
case of left ventricular failure, or during high-risk revascularisation procedures with 
potential postcardiotomy weaning complications, as a cost-effective bridge- to-deci-
sion or bridge-to-bridge solution. The use of device ensures a fast and cost-effective 
implementation, due to a universally adaptable design that fully integrates with any 
standard IABP console. Patients have faster post-operative mobility with subclavian 
or axillary artery access. With the increase in more complex and higher risk cases, 
the incidence of postcardiotomy failure has now begun to rise. Currently, about 6 % 
of patients develop postcardiotomy ventricular failure. The iVAC 3L™ is indicated 
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for OPCAB procedures (recovery support); postcardiotomy weaning complications; 
cases of cardiogenic shock; acute myocardial infarction. At 3 l/m, the iVAC 3L™ does 
the job when an IABP is insufficient for the demand, and a higher-cost and more 
complicated LVAD may not be warranted. The iVAC 3L™ provides the cardiologist 
and cardiac surgeon with additional life saving options, and opens previously not 
available procedural possibilities. The use of this device unloads the left ventricle 
and increases circulatory blood flow; reduces the myocardial workload allowing 
the heart to rest and heal; potentially avoids the need for inotropes during CPB we-
aning; lowers the anticoagulation requirements; increases the coronary artery and 
end-organ perfusion; and finally, lowers the risk of haemodynamic deterioration. 
The iVAC 3L™ incorporates a patented rotating two-way valve, which is connected 
to an extracorporeal dual chamber membrane housing via a 21 Fr. lumen catheter. 
It can be used with any standard IABP driver unit and does not require dedicated 
hardware. When the heart is in the systolic phase, the blood flows from the ven-
tricle through the catheter tip and is aspirated into the membrane housing. During 
the diastolic phase, the membrane pushes the blood back through the catheter, su-
bsequently opening the valve and delivering the blood to the aorta through the side 
outflow port. The device directly unloads the heart by active aspiration from the left 
ventricle and simultaneously creates a pulsatile flow in the ascending aorta. The use 
of this device provides many advantages, such as: the aortic blood-flow increase; the 
mean arterial blood pressure improvement; the myocardial perfusion increase; the 
after-load reducement; the end systolic LV volume reducement; and the myocardial 
demand decrease by reducing the cardiac work.
Centrifugal pumps have been used both for intra-operative cardiopulmonary 
bypass and as a means of providing right, left, or biventricular mechanical circula-
tory support. They have following advantages: wide availability, the ease of use, and 
relative low cost when compared to other devices. Disadvantages include the need 
for systemic anticoagulation with resultant bleeding complications. The progressive 
development of interstitial oedema secondary to capillary leak and the inability to 
ambulate and rehabilitate these patients limit this technology to short-term support. 
Some of the most commonly used pumps are the Biomedicus Biopump (Medtro-
nic Bio-Medicus, Inc., Eden Prairie, Minn); the Sarns centrifugal pump (3-M Health 
Care, Ann Arbor, Mich); and the St. Jude Lifestream centrifugal pump (St. Jude Me-
dical, Inc., St. Paul, Minn).
The Levitronix CentriMag short-term LVAS comprises a single-use centrifugal 
pump, a motor, and a primary drive console. Compared to other devices, the Levi-
tronix LVAS is unique insofar that it is designed to operate with no mechanical be-
arings or seals. This is possible since the motor magnetically levitates the impeller, 
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achieving rotation with no friction or wear. The Levitronix CentriMag is a continu-
ous-flow, centrifugal-type rotary blood pump that is placed outside the body (extra-
corporeally). The pump housing and the rotor are made of medical-grade polycar-
bonate, designed for single use. The only moving component within the pump is the 
impeller, which is magnetically levitated and rotated in a contact-free manner. The 
centrifugal pump design permits the rotation of the impeller at lower speeds, while 
still achieving the desired flow rates. The pump can rotate at the speeds from 1,500 
rpm to 5,500 rpm, and can provide the flow rates of up to 9.9 litres per minute. The 
Levitronix pump causes very little damage to the blood, as it contains no bearings or 
seals – components known to cause haemolysis and promote thrombus formation. 
Moreover, the pump does not contain any flexing sacs, diaphragms, or valves, mini-
mising thereby the risk of component failure and device-related adverse effects.
The extracorporeal membrane oxygenation (ECMO) utilises a centrifugal pump 
in combination with a membrane oxygenator to provide complete cardiopulmonary 
support in the setting of circulatory and respiratory failure. The successful use of 
ECMO in the paediatric population has been well described [20]. The outcome of 
ECMO for the treatment of cardiac failure in the adult population is more limited.
The TandemHeart percutaneous VAD (CardiacAssist, Inc., Pittsburgh, Penn) 
utilises a centrifugal pump that pumps blood from the left atrium to one or both 
femoral arteries. The left atrial catheter is placed percutaneously via a trans-septal 
puncture [21].
The Impella Recover device (Impella CardioSystems AG, Aachen, Germany) is a 
miniature axial flow pump designed for short-term right, left, or biventricular sup-
port. The device is able to generate flows of up to 4 to 5 L/min at the rotational speeds 
of between 28,000 and 32,000 rpm. The device has the advantage of being easily im-
planted and having minimal requirement for anticoagulation. The device can be 
placed percutaneously and positioned with echocardiographic guidance [22].
The Abiomed BVS 5000i (Abiomed Cardiovascular, Inc., Danvers, Mass) is a de-
vice for acute postcardiotomy failure. It is a dual-chambered, pneumatically driven 
extracorporeal pump, designed for short-term cardiac support. The dual chamber 
polyurethane blood sacs fill passively, with pneumatically driven ejection. The con-
figuration mimics that of the native atria and ventricles. The device is capable of 
generating a pulsatile flow of up to 6 L/min. The ease of implantation, operation, we-
aning, cost-effectiveness, and widespread availability have made it one of the most 
commonly used devices in the setting of acute cardiac failure. The indications for its 
use have expanded beyond the postcardiotomy setting, to include the cardiogenic 
shock associated with acute infarction; myocarditis; and temporary right ventricu-
lar support in association with long-term LVAD implantation.
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The MAQUET Heart Lung Support (HLS) system including CARDIOHELP and 
the disposable HLS Set and HLS Cannulae is a very light and small life support 
system. The portable system provides extracorporeal life support (ECLS), to replace 
or support the patient’s circulation and respiration, the so-called cardiopulmonary 
support. The device is light enough to be carried by one person, and compact eno-
ugh to be transported in a helicopter or vehicle. With its disposables, its integrated 
sensors and its software versions, the CARDIOHELP life support system opens up 
new possibilities for patients requiring veno-venous ECLS or veno-arterial ECLS, as 
well as for CO2 removal and the use of minimal extracorporeal circulation (MECC). 
Vessel access is needed to link the extracorporeal life support (ECLS) system to the 
patient. Special HLS Cannulae can be gently percutaneously inserted into appro-
priate veins and arteries for cardiac support and/or respiratory assistance. Some 
authors reported in observational study that extracorporeal cardiopulmonary re-
suscitation (CPR) has a short-term and long-term survival benefit over patients with 
conventional CPR in patients with in-hospital cardiac arrest of cardiac origin [23].
The AB5000 Circulatory Support System provides temporary support for one or 
both sides of the natural heart in circumstances where the heart has failed, giving 
the patient’s heart an opportunity to rest and potentially recover. The AB5000 Ven-
tricle is vacuum-assisted technology with clear housing to allow clinicians a view 
into the device. It uses the same cannula as the previously described BVS 5000 Blood 
Pumps, allowing for a seamless transition of devices without requiring any additi-
onal surgical procedure. Unlike other ventricular assist systems that can require 
multiple drivers for a single patient, patients on the AB5000 Ventricle require only 
a single console – regardless of their condition. The AB5000 Console is designed to 
allow patients to leave their hospital rooms and walk within the hospital and on 
hospital grounds. Multiple studies have shown that patient ambulation, or walking, 
assists the recovery process greatly. The ease of use and the transport capability of 
the AB5000 System make it an important option for both regional and local cardiac 
centres, and enable a patient to be transported to a more advanced cardiac centre if 
necessary.
POST-OPERATIVE MANAGEMENT AND COMPLICATIONS
In the immediate peri-operative period, proper device function and meticulo-
us post-operative care must be ensured in order to maintain adequate end-organ 
perfusion. Antibiotic prophylaxis begins pre-operatively, and is usually continu-
ed for 48 to 72 hours post-operatively. 24 to 36 hours after implantation, systemic 
anticoagulation with heparin and warfarin is initiated. Patients should be weaned 
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from mechanical ventilatory support as soon as feasible. Diuretics are administered 
early in the post-operative course, since many of these patients are in a chronic vo-
lume-overloaded state. Peri-operative renal insufficiency is usually managed with 
the early institution of continuous veno-venous haemofiltration for the optimisation 
of fluid balance. Since the publication of the landmark REMATCH (Randomized 
Evaluation of Mechanical Assistance for the Treatment of Congestive Heart Failure) 
trial in 2001, refinement in devices and the adoption of best practice management te-
chniques have improved the short- and long-term patient care [24,25]. Peri-operative 
complications include haemorrhage; right ventricular failure; sepsis; air embolism; 
and kinking of conduits. The most common late complications are mechanical devi-
ce failure, neurological events, and infection [2,26,27].
Herein, we describe some of the most common complications:
Mediastinal bleeding following left ventricular assist device implantation is 
relatively common and may be related to systemic anticoagulation or the potenti-
ally acquired von Willebrand disease [28]. The predisposing factors include hepatic 
congestion and dysfunction related to chronic heart failure; compromised nutriti-
onal status; the use of pre-operative anticoagulation; extensive surgical dissection; 
re-operative procedures; prolonged cardiopulmonary bypass; and coagulopathy 
secondary to interactions between the circulating blood elements and the artificial 
device surfaces [29]. Of note late bleeding and tamponade can occur due to the requ-
irement of systemic anticoagulation.
Sepsis due to infection is the leading cause of death in patients receiving ven-
tricular assist devices2. Infections in LVAD patients can affect different components 
of the device and can vary in severity. Patients can also develop infectious compli-
cations at sites remote from the device such as in the respiratory, gastrointestinal, 
or genitourinary tracts, as well as from indwelling intravenous and central lines. 
Other patient factors, which may increase the susceptibility to infection, include ge-
neralised debilitation and malnutrition, diabetes, renal failure, and immunologic 
derangements associated with T-cell death seen after device implantation [30]. VAD 
infections can occur at any time, but most frequently, they occur between 2 weeks 
and 2 months after the implantation. Bacteria that are able to form biofilm, such as 
Staphylococcus, Pseudomonas, or Enterococcus, predominantly cause device-rela-
ted infections. The frequent use of broad-spectrum antibiotics increase susceptibili-
ty for fungal infections, which are associated with the highest risk of death [31].
Implanted mechanical devices are susceptible to thromboembolic events due to 
their unique properties. The foreign surfaces of VADs can activate the immune sy-
stem, platelets, and the coagulation cascade. In addition, the blood-contact surfaces 
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of VADs, along with the turbulent blood flow, increase the risk of shear stress on 
the blood and thrombi formation. Intracranial haemorrhage, syncope, seizure, brain 
abscesses, and encephalopathy have all been reported. These data mostly originate 
from the bridge-to-transplantation experience, and may not apply to destination 
therapy patients, who are generally older, and have more comorbidities and longer 
implantation periods. Not all devices have the same neurological event rate, and 
design modifications incorporated in the newer generation of VADs, including the 
use of novel biologic materials, textured coatings, and a single moving part, are 
believed to reduce the risk of thrombus formation. All device patients are mainta-
ined on aspirin, mainly for its anti-inflammatory effect, and most devices require 
anticoagulation with heparin and warfarin. The vigilant control of anticoagulation 
parameters is necessary to balance the risk of thrombus formation with the threat of 
late mediastinal bleeding.
Approximately 20 % of patients undergoing left ventricular assist device pla-
cement will suffer from post-operative right heart failure [32]. Predicting which 
patients will manifest right-sided failure can be difficult. The post-operative right 
ventricular failure has a significant effect on the clinical outcomes, leading to incre-
ased length of stay in the intensive care unit; increased 30-day mortality following 
the LVAD implantation; and a lower bridge-to-transplantation rate. Clinically, the 
onset of the right ventricular failure can be sudden, and may occur at the onset of 
an LVAD device initiation. The blood product transfusion has been shown to have 
adverse effects on pulmonary vascular resistance [33]. The use of aprotinin has been 
shown to decrease the blood loss, the incidence of the right VAD implantation, and 
the peri-operative mortality in patients undergoing LVAD placement [34].
A significant proportion of patients undergoing the device placement experi-
ence a multi-system organ failure that carries a high mortality in patients. Patients 
undergoing the VAD implantation have a high incidence of comorbidities, and many 
manifest significant end-organ dysfunctions pre-operatively. Some may not recover 
the organ function following the device implantation. Other patients may manifest 
multi-system organ failure as the end result of complications related to device im-
plantation. These include surgical trauma, prolonged cardiopulmonary bypass ti-
mes, peri-operative bleeding, and sepsis.
Device failure is an ever-present concern in patients with mechanical circula-
tory assistance. Both cardiac catheterisation and transesophageal echocardiography 
have been described as useful tools for the diagnosis of device malfunction.
Immunologic effects and allosensitization are derived from the interaction 
between prosthetic device surfaces and circulating blood elements. A number of al-
terations are seen in the T-cell function. T cells in LVAD patients demonstrated an 
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increased susceptibility to activation-induced cell death. Another aspect of the im-
munologic disturbance that is seen is the B-cell hyper-reactivity. The overall clinical 
effect of these changes is two-fold. First, patients demonstrate progressive defects in 
cellular immunity, with a resultant increased risk of infection. Second, B-cell hyper-
reactivity ultimately leads to allosensitization to human leukocyte antigens. Untre-
ated allosensitization is associated with prolonged pre-transplant waiting times, as 
well as an increased risk of acute rejection. When sensitisation develops, immuno-
modulation with intravenous immunoglobulin therapy in conjunction with cyclop-
hosphamide has proven to be effective in reducing alloreactivity, and reducing the 
risk of acute rejection [35]. 
CONCLUSION
Mechanical circulatory support has emerged as an important therapeutic option 
in the treatment of both acute and chronic heart failure of various aetiologies. As 
VAD technology progresses, the collaboration of multidisciplinary teams composed 
of engineers, scientists, physicians, and nurses will continue to refine the techno-
logy and improve patient care and operation outcomes. Advances in device design 
will allow for an easier implantation and create smaller, more efficient, durable, and 
reliable units. Active areas of investigation include the effects of mechanical un-
loading on ventricular remodelling, as well as the potential use of device support 
in conjunction with other modalities, such as gene therapy; pharmacotherapy; and 
stem cell implantation to promote myocardial recovery. 
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Sažetak
Kratkotrajna potpora cirkulaciji i izmjeni plinova u krvi
Zatajenje srca s porastom incidencije i prevalencije u sve starijoj populaciji polako postaje 
javno zdravstveni problem. Mehanička cirkulacijska potpora se koristi kao oblik liječenja u sku-
pini bolesnika s uznapredovalim zatajenjem srca. Mehanička crpka se kirurški implantira kako bi 
osigurala, bilo pulsatilni, bilo nepulsatilni protok krvi koji služi kao supplement ili kao zamjena 
protoku krvi kojeg bi trebalo generirati srce. Glavni cilj i namjena mehaničke cirkulacijske pot-
pore je volumno rasteretiti srce u terminalnom zatajenju i pomoći u održavanju protoka vitalnih 
organa održavajući minutni volumen. Prisutna je široka paleta uređaja: od onih koji se mogu 
perkutano implantirati, uređaja za kratkoročnu potporu koji se mogu koristiti u operacijskoj sali, 
u laboratoriju za kateterizaciju kao i u jedinici intenzivnog liječenja do potpuno implantibilnih 
uređaja za dugoročnu potporu. Uređaji mogu biti korišteni kao terapija premoštenja do opo-
ravka ili do transplantacije srca ili, u pojedinim slučajevima, uređaji predstavljaju definitivnu 
terapiju, npr. kod bolesnika u kojih je kontraindicirana transplantacija. Ovaj oblik liječenja ne 
uključuje samo kardiokirurge, već i kardiologe, anesteziologe kao i perfuzioniste. Pravilna tri-
jaža bolesnika predstavlja ključnu točku uspjeha u ishodu liječenja volesnika s mehaničkom 
cirkulacijskom potporom. Prijeoperacijska stratifikacija rizika je iznimno važna u minimalizira-
nju stope perioperacijsakog mortaliteta. Istovremeni tehnološki razvoj, kao i multidisciplinarna 
suradnja konstruktora uređaja, znanstvenika, liječnika i ostalog medicinskog osoblja dovest će 
do unaprijeđenja cjelokupnog procesa liječenja ove skupine bolesnika. Daljnji tehnološki razvoj 
ide u smjeru pojednostavljenja procesa implantacije, s manjim, efikasnijim, trajnijim i još više 
pouzdanijim uređajima.
Ključne riječi: mehanička cirkulacijska potpora; zatajenje srca

